Nasdaq · CIK 0001785530
HOWL Werewolf Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jul 8, 2026. Close $0.98 on Oct 9, 2026, +218% from the 52-week low and -45% from the high.
In brief
Werewolf Therapeutics, Inc. (HOWL) has 69 SEC Form 4 filings on file from 4 insiders, the latest filed on Jul 8, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
57 open-market trades have been scored at HOWL. The newest: Luke Evnin (director) sold $45k of stock on Jul 6, 2026, filed Jul 8, 2026, scored 21 (weak), under a 10b5-1 plan. The largest of the 50 shown: Ansbert Gadicke (10% owner) sold $392k on Oct 30, 2025, scored 23 (weak), under a 10b5-1 plan. 2 insiders sold within 14 days of each other around Jun 29, 2026.
25 Form 144 notices of planned sales are on file, the latest filed Jul 6, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
4
with a Form 4 at this company
Price and insider trades, last year
HOWLOct 9, 2026 · close 0.98
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Werewolf Therapeutics, Inc., scored: the newest 50 of 57.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Luke Evnin director sell | $45k 143,199 shares | -100% | +4% from low-85% from high | |
| 29Weak | Luke Evnin director sell | $47k 157,084 shares | -52% | 0% from low-86% from high | |
| 31Weak | Ra Capital Management, L.p. owner sell | $146k 416,911 shares | -9% | 0% from low-84% from high | |
| 31Weak | Ra Capital Management, L.p. owner sell | $174k 448,836 shares | -9% | +4% from low-83% from high | |
| 38Weak | Ra Capital Management, L.p. owner sell | $254k 678,226 shares | -12% | 0% from low-83% from high | |
| 13Weak | Luke Evnin director sell | $28k 76,928 shares | -20% | 0% from low-83% from high | |
| 14Weak | Luke Evnin director sell | $43k 105,565 shares | -22% | +2% from low-80% from high | |
| 16Weak | Luke Evnin director sell | $64k 139,803 shares | -22% | +10% from low-79% from high | |
| 16Weak | Luke Evnin director sell | $66k 141,106 shares | -18% | +16% from low-78% from high | |
| 17Weak | Luke Evnin director sell | $87k 191,762 shares | -20% | 0% from low-81% from high | |
| 16Weak | Luke Evnin director sell | $76k 171,049 shares | -15% | 0% from low-77% from high | |
| 3Weak | Luke Evnin director sell | $24k 44,679 shares | -4% | +6% from low-73% from high | |
| 27Weak | Luke Evnin director sell | $280k 407,574 shares | -26% | +24% from low-69% from high | |
| 36Weak | Ra Capital Management, L.p. owner sell | $391k 565,167 shares | -9% | +24% from low-69% from high | |
| 11Weak | Luke Evnin director sell | $64k 100,581 shares | -6% | +22% from low-69% from high | |
| 20Weak | Luke Evnin director sell | $198k 274,619 shares | -14% | +31% from low-67% from high | |
| 14Weak | Luke Evnin director sell | $155k 205,911 shares | -10% | +51% from low-62% from high | |
| 0Weak | Luke Evnin director sell | $21k 38,782 shares | -2% | 0% from low-75% from high | |
| 2Weak | Luke Evnin director sell | $62k 111,227 shares | -5% | 0% from low-74% from high | |
| 2Weak | Luke Evnin director sell | $54k 91,374 shares | -4% | +3% from low-71% from high | |
| 1Weak | Luke Evnin director sell | $46k 71,054 shares | -3% | +5% from low-71% from high | |
| 2Weak | Luke Evnin director sell | $48k 78,377 shares | -3% | 0% from low-72% from high | |
| 12Weak | Luke Evnin director sell | $185k 291,283 shares | -10% | +6% from low-69% from high | |
| 17Weak | Luke Evnin director sell | $52k 48,171 shares | -2% | - | |
| 19Weak | Luke Evnin director sell | $89k 82,971 shares | -3% | - | |
| 20Weak | Luke Evnin director sell | $95k 95,179 shares | -3% | - | |
| 20Weak | Luke Evnin director sell | $118k 128,185 shares | -4% | - | |
| 15Weak | Ansbert Gadicke other sell | $183k 199,732 shares | -4% | - | |
| 15Weak | MPM BioVentures 2014, L.P. other sell | $183k 199,732 shares | -4% | - | |
| 19Weak | Luke Evnin director sell | $88k 91,088 shares | -3% | - | |
| 18Weak | Ansbert Gadicke owner sell | $137k 141,927 shares | -3% | - | |
| 18Weak | MPM BioVentures 2014, L.P. owner sell | $137k 141,927 shares | -3% | - | |
| 20Weak | Luke Evnin director sell | $115k 125,576 shares | -4% | - | |
| 19Weak | Ansbert Gadicke owner sell | $180k 195,666 shares | -4% | - | |
| 19Weak | MPM BioVentures 2014, L.P. owner sell | $180k 195,666 shares | -4% | - | |
| 20Weak | Luke Evnin director sell | $95k 102,753 shares | -3% | - | |
| 18Weak | Ansbert Gadicke owner sell | $148k 160,103 shares | -3% | - | |
| 18Weak | MPM BioVentures 2014, L.P. owner sell | $148k 160,103 shares | -3% | - | |
| 21Weak | Luke Evnin director sell | $129k 134,553 shares | -4% | - | |
| 19Weak | Ansbert Gadicke owner sell | $201k 209,652 shares | -4% | - | |
| 19Weak | MPM BioVentures 2014, L.P. owner sell | $201k 209,652 shares | -4% | - | |
| 21Weak | Luke Evnin director sell | $155k 137,041 shares | -4% | - | |
| 20Weak | Ansbert Gadicke owner sell | $241k 213,529 shares | -4% | - | |
| 20Weak | MPM BioVentures 2014, L.P. owner sell | $241k 213,529 shares | -4% | - | |
| 22Weak | Luke Evnin director sell | $190k 155,885 shares | -4% | - | |
| 21Weak | Ansbert Gadicke owner sell | $296k 242,890 shares | -4% | - | |
| 21Weak | MPM BioVentures 2014, L.P. owner sell | $296k 242,890 shares | -4% | - | |
| 23Weak | Luke Evnin director sell | $251k 189,356 shares | -5% | - | |
| 23Weak | Ansbert Gadicke owner sell | $392k 295,043 shares | -5% | - | |
| 23Weak | MPM BioVentures 2014, L.P. owner sell | $392k 295,043 shares | -5% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 6, 2026 | MPM Asset Management LLC Shareholder | 15,341 0.03% of outstanding | $5,222 | Jul 6, 2026 | none |
| Jul 6, 2026 | MPM Asset Management Investors BV2014 LLC Shareholder | 3,332 0.01% of outstanding | $1,134 | Jul 6, 2026 | none |
| Jul 6, 2026 | MPM BioVentures 2014 (B), L.P. Shareholder | 6,459 0.01% of outstanding | $2,199 | Jul 6, 2026 | none |
| Jul 6, 2026 | MPM BioVentures 2014, L.P. Shareholder | 96,873 0.20% of outstanding | $33k | Jul 6, 2026 | none |
| Jul 6, 2026 | MPM Oncology Innovations Fund, L.P. Shareholder | 21,194 0.04% of outstanding | $7,214 | Jul 6, 2026 | none |
| Jul 6, 2026 | UBS Oncology Impact Fund, L.P. Shareholder | 80,142 0.16% of outstanding | $27k | Jul 6, 2026 | none |
| Jun 29, 2026 | MPM Asset Management LLC Shareholder | 16,830 0.03% of outstanding | $5,436 | Jun 29, 2026 | none |
| Jun 29, 2026 | MPM Asset Management Investors BV2014 LLC Shareholder | 3,657 0.01% of outstanding | $1,181 | Jun 29, 2026 | none |
| Jun 29, 2026 | MPM BioVentures 2014 (B), L.P. Shareholder | 7,087 0.01% of outstanding | $2,289 | Jun 29, 2026 | none |
| Jun 29, 2026 | MPM BioVentures 2014, L.P. Shareholder | 106,262 0.22% of outstanding | $34k | Jun 29, 2026 | none |
| Jun 29, 2026 | MPM Oncology Innovations Fund, L.P. Shareholder | 23,248 0.05% of outstanding | $7,509 | Jun 29, 2026 | none |
| Jun 29, 2026 | UBS Oncology Impact Fund, L.P. Shareholder | 87,916 0.18% of outstanding | $28k | Jun 29, 2026 | none |
| May 28, 2026 | MPM Asset Management LLC Shareholder | 38,675 0.08% of outstanding | $19k | May 28, 2026 | none |
| May 28, 2026 | MPM Asset Management Investors BV2014 LLC Shareholder | 8,405 0.02% of outstanding | $4,118 | May 28, 2026 | none |
| May 28, 2026 | MPM BioVentures 2014 (B), L.P. Shareholder | 16,287 0.03% of outstanding | $7,981 | May 28, 2026 | none |
| May 28, 2026 | MPM BioVentures 2014, L.P. Shareholder | 244,185 0.50% of outstanding | $120k | May 28, 2026 | none |
| May 28, 2026 | MPM Oncology Innovations Fund, L.P. Shareholder | 53,425 0.11% of outstanding | $26k | May 28, 2026 | none |
| May 28, 2026 | UBS Oncology Impact Fund, L.P. Shareholder | 202,029 0.42% of outstanding | $99k | May 28, 2026 | none |
| May 18, 2026 | MPM Asset Management LLC Shareholder | 45,998 0.09% of outstanding | $24k | May 18, 2026 | none |
| May 18, 2026 | MPM Asset Management Investors BV2014 LLC Shareholder | 9,996 0.02% of outstanding | $5,149 | May 18, 2026 | none |
| May 18, 2026 | MPM BioVentures 2014 (B), L.P. Shareholder | 19,370 0.04% of outstanding | $9,977 | May 18, 2026 | none |
| May 18, 2026 | MPM BioVentures 2014, L.P. Shareholder | 290,419 0.60% of outstanding | $150k | May 18, 2026 | none |
| May 18, 2026 | MPM Oncology Innovations Fund, L.P. Shareholder | 63,540 0.13% of outstanding | $33k | May 18, 2026 | none |
| May 18, 2026 | UBS Oncology Impact Fund, L.P. Shareholder | 240,280 0.49% of outstanding | $124k | May 18, 2026 | none |
| May 11, 2026 | MPM Asset Management LLC Shareholder | 13,382 0.03% of outstanding | $9,100 | May 11, 2026 | none |
Transactions
The newest 50 of 194 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 6, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -35,770 | $0.32 | $11k | 107,429 | Jul 8, 2026 |
| Jul 7, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -107,429 | $0.31 | $33k | 0 | Jul 8, 2026 |
| Jun 29, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -157,084 | $0.30 | $47k | 143,199 | Jun 29, 2026 |
| Jun 17, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -389,216 | $0.35 | $136k | 4,268,448 | Jun 22, 2026 |
| Jun 17, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -27,695 | $0.35 | $9,693 | 303,719 | Jun 22, 2026 |
| Jun 12, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -159,119 | $0.40 | $64k | 4,917,566 | Jun 16, 2026 |
| Jun 12, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -11,322 | $0.40 | $4,529 | 349,907 | Jun 16, 2026 |
| Jun 15, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -120,216 | $0.39 | $47k | 4,797,350 | Jun 16, 2026 |
| Jun 15, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -8,554 | $0.39 | $3,336 | 341,353 | Jun 16, 2026 |
| Jun 16, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -139,686 | $0.37 | $52k | 4,657,664 | Jun 16, 2026 |
| Jun 16, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -9,939 | $0.37 | $3,677 | 331,414 | Jun 16, 2026 |
| Jun 9, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -345,235 | $0.37 | $128k | 5,364,623 | Jun 11, 2026 |
| Jun 9, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -24,565 | $0.37 | $9,089 | 381,717 | Jun 11, 2026 |
| Jun 10, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -42,872 | $0.37 | $16k | 5,321,751 | Jun 11, 2026 |
| Jun 10, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -3,051 | $0.37 | $1,129 | 378,666 | Jun 11, 2026 |
| Jun 11, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -245,066 | $0.38 | $93k | 5,076,685 | Jun 11, 2026 |
| Jun 11, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -17,437 | $0.38 | $6,626 | 361,229 | Jun 11, 2026 |
| Jun 9, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -76,928 | $0.37 | $28k | 300,283 | Jun 10, 2026 |
| Jun 4, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -20,072 | $0.44 | $8,832 | 462,704 | Jun 8, 2026 |
| Jun 5, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -24,946 | $0.40 | $9,978 | 437,758 | Jun 8, 2026 |
| Jun 8, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -60,547 | $0.40 | $24k | 377,211 | Jun 8, 2026 |
| Jun 1, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -80,459 | $0.47 | $38k | 542,120 | Jun 3, 2026 |
| Jun 2, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -29,595 | $0.45 | $13k | 512,525 | Jun 3, 2026 |
| Jun 3, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -29,749 | $0.42 | $12k | 482,776 | Jun 3, 2026 |
| May 27, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -80,852 | $0.48 | $39k | 682,833 | May 29, 2026 |
| May 28, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -27,698 | $0.46 | $13k | 655,135 | May 29, 2026 |
| May 29, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -32,556 | $0.45 | $15k | 622,579 | May 29, 2026 |
| May 21, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -36,387 | $0.42 | $15k | 919,060 | May 26, 2026 |
| May 22, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -87,425 | $0.45 | $39k | 831,635 | May 26, 2026 |
| May 26, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -67,950 | $0.47 | $32k | 763,685 | May 26, 2026 |
| May 18, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -22,184 | $0.50 | $11k | 1,104,312 | May 20, 2026 |
| May 19, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -62,970 | $0.45 | $28k | 1,041,342 | May 20, 2026 |
| May 20, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -85,895 | $0.43 | $37k | 955,447 | May 20, 2026 |
| May 13, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -44,679 | $0.54 | $24k | 1,126,496 | May 13, 2026 |
| May 8, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -305,741 | $0.70 | $214k | 1,273,008 | May 12, 2026 |
| May 8, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -351,514 | $0.71 | $250k | 5,885,968 | May 12, 2026 |
| May 11, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -33,948 | $0.67 | $23k | 1,239,060 | May 12, 2026 |
| May 8, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -25,012 | $0.71 | $18k | 418,813 | May 12, 2026 |
| May 12, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -67,885 | $0.64 | $43k | 1,171,175 | May 12, 2026 |
| May 11, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -81,678 | $0.67 | $55k | 5,804,290 | May 12, 2026 |
| May 11, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -5,812 | $0.67 | $3,894 | 413,001 | May 12, 2026 |
| May 12, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -94,432 | $0.64 | $60k | 5,709,858 | May 12, 2026 |
| May 12, 2026 | Ra Capital Management, L.p. owner | SOpen-market sale Common Stockindirect: See footnotes | -6,719 | $0.64 | $4,300 | 406,282 | May 12, 2026 |
| May 5, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -6,860 | $0.69 | $4,733 | 1,672,470 | May 7, 2026 |
| May 6, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -14,635 | $0.66 | $9,659 | 1,657,835 | May 7, 2026 |
| May 7, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -79,086 | $0.63 | $50k | 1,578,749 | May 7, 2026 |
| Apr 30, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -168,262 | $0.72 | $121k | 1,785,687 | May 4, 2026 |
| May 1, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -58,394 | $0.73 | $43k | 1,727,293 | May 4, 2026 |
| May 4, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -47,963 | $0.72 | $35k | 1,679,330 | May 4, 2026 |
| Apr 27, 2026 | Luke Evnin director | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -53,940 | $0.85 | $46k | 2,105,920 | Apr 29, 2026 |
50 of 194 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Luke Evninowner, director, other
- Ansbert Gadickeowner, other
- MPM BioVentures 2014, L.P.owner, other
- Ra Capital Management, L.p.owner, director
Questions about HOWL
Answered from the filings on this page, as of the latest one.
Are insiders buying HOWL?
No. In the last 90 days no insider at Werewolf Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade HOWL on the open market?
Luke Evnin (director) sold $45k of HOWL on Jul 6, 2026 and filed the Form 4 on Jul 8, 2026. InsiderTell scored 21 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at Werewolf Therapeutics, Inc.?
4 people have filed a Form 4 at Werewolf Therapeutics, Inc., among them Luke Evnin (10% owner and director), Ansbert Gadicke (10% owner), MPM BioVentures 2014, L.P. (10% owner). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.